English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/115426
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Citado 15 veces en Web of Knowledge®  |  Pub MebCentral Ver citas en PubMed Central  |  Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar otros formatos: Exportar EndNote (RIS)Exportar EndNote (RIS)Exportar EndNote (RIS)
Título

Phosphorylation at ser-181 of oncogenic KRAS is required for tumor growth

Autor Barceló, Carles; Paco, Noelia; Morell, Mireia; Álvarez-Moya, Blanca; Bota-Rabassedas, Neus ; Jaumot, Montserrat; Vilardell, Felip; Capellá, Gabriel; Agell, Neus
Fecha de publicación 15-feb-2014
EditorAmerican Association for Cancer Research
Citación Cancer Research 74: 1190-1199 (2014)
ResumenKRAS phosphorylation has been reported recently to modulate the activity of mutant KRAS protein in vitro. In this study, we defined S181 as a specific phosphorylation site required to license the oncogenic function of mutant KRAS in vivo. The phosphomutant S181A failed to induce tumors in mice, whereas the phosphomimetic mutant S181D exhibited an enhanced tumor formation capacity, compared with the wild-type KRAS protein. Reduced growth of tumors composed of cells expressing the nonphosphorylatable KRAS S181A mutant was correlated with increased apoptosis. Conversely, increased growth of tumors composed of cells expressing the phosphomimetic KRAS S181D mutant was correlated with increased activation of AKT and ERK, two major downstream effectors of KRAS. Pharmacologic treatment with PKC inhibitors impaired tumor growth associated with reduced levels of phosphorylated KRAS and reduced effector activation. In a panel of human tumor cell lines expressing various KRAS isoforms, we showed that KRAS phosphorylation was essential for survival and tumorigenic activity. Furthermore, we identified phosphorylated KRAS in a panel of primary human pancreatic tumors. Taken together, our findings establish that KRAS requires S181 phosphorylation to manifest its oncogenic properties, implying that its inhibition represents a relevant target to attack KRAS-driven tumors. © 2014 American Association for Cancer Research.
URI http://hdl.handle.net/10261/115426
DOI10.1158/0008-5472.CAN-13-1750
Identificadoresdoi: 10.1158/0008-5472.CAN-13-1750
issn: 0008-5472
e-issn: 1538-7445
Aparece en las colecciones: (IBE) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 



NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.